John Aballi Biography and Net Worth

CEO of Exagen

John Aballi has served as President and CEO since October 2022. He most recently served as SVP, GM, Urology and CLIA COO for Veracyte, a San Francisco based molecular diagnostic company. In this role, he maintained P&L responsibility for the business unit, ultimately expanding the urology franchise to $120 million-plus in annual revenue while maintaining responsibility for the company’s market access, billing and customer service functions in addition to Veracyte’s four US-based CLIA laboratories. Prior to this role, Mr. Aballi was a key member of the leadership team which transformed Decipher Biosciences to the market leader in genomic testing for prostate cancer. Decipher Biosciences was sold to Veracyte in March 2021 for $600 million and Mr. Aballi served as the SVP & Chief Operating Officer at the company, responsible for all aspects of operations including sales, quality management, medical operations, customer service, software development, assay development, billing, managed care, and laboratory operations; he assumed this role in August 2018. Mr. Aballi previously served as the Head of Operations at Molecular Stethoscope, a company developing cell-free RNA based diagnostics, from September 2015 to August 2018. Prior to joining Molecular Stethoscope, Mr. Aballi served in various senior roles at Genoptix from January 2007 to September 2015. Mr. Aballi was a Board Member of PFS Genomics in San Diego, a molecular diagnostic company specializing in proprietary signature development in breast cancer, which was acquired by Exact Sciences in 2021. He holds an MBA from California Baptist University and dual degrees from UC San Diego in biochemistry and cell biology and economics.

What is John Aballi's net worth?: The estimated net worth of John Aballi is at least $4.65 million as of March 3rd, 2026. Aballi owns 687,299 shares of Exagen stock worth more than $4,646,141 as of August 7th. This net worth evaluation does not reflect any other assets that Aballi may own. Learn More about John Aballi's net worth.
How do I contact John Aballi?: The corporate mailing address for Aballi and other Exagen executives is 1261 Liberty Way Suite C, VISTA CA, 92081. Exagen can also be reached via phone at 760-560-1501 and via email at [email protected]. Learn More on John Aballi's contact information.
Has John Aballi been buying or selling shares of Exagen?: John Aballi has not been actively trading shares of Exagen during the last ninety days. Most recently, John Aballi sold 15,698 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $3.62, for a transaction totalling $56,826.76. Following the completion of the sale, the chief executive officer now directly owns 687,299 shares of the company's stock, valued at $2,488,022.38. Learn More on John Aballi's trading history.
Who are Exagen's active insiders?: Exagen's insider roster includes John Aballi (CEO), John Aballi (CEO), Wendy Johnson (Director), and James Tullis (Director). Learn More on Exagen's active insiders.
Are insiders buying or selling shares of Exagen?: In the last year, insiders at the sold shares 3 times. They sold a total of 58,915 shares worth more than $473,811.40. The most recent insider tranaction occured on March, 3rd when CEO John Aballi sold 15,698 shares worth more than $56,826.76. Insiders at Exagen own 10.4% of the company. Learn More about insider trades at Exagen.
Information on this page was last updated on 3/3/2026.

John Aballi Insider Trading History at Exagen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/3/2026	Sell	15,698	$3.62	$56,826.76	687,299
2/24/2026	Sell	11,430	$3.61	$41,262.30	702,997
10/16/2025	Sell	31,787	$11.82	$375,722.34	714,427
11/14/2024	Buy	24,305	$2.81	$68,297.05	689,799
5/16/2024	Buy	40,401	$1.92	$77,569.92	40,401
10/17/2023	Sell	33,819	$1.75	$59,183.25	415,984
12/8/2022	Buy	90,000	$2.68	$241,200.00	440,000

John Aballi Buying and Selling Activity at Exagen

Exagen Company Overview

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Today's Range

Now: $6.84

$6.48

$6.94

50 Day Range

MA: $4.67

$4.09

$6.65

2 Week Range

Now: $6.84

$2.59

$12.23

Volume

327,296 shs

Average Volume

414,470 shs

Market Capitalization

$165.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05